News Snapshot:
China's Harbour Biomed, a clinical-stage biopharmaceutical company, has hit the road for its up to HK$1.8bn ($230.4m) listing. The issuer, floating in Hong Kong through HBM Holdings, was founded in 2016 for the discovery and development of antibody therapies for immunology and oncology. The listing sponsors Bank of America, CLSA and Morgan Stanley began taking orders for the IPO on Monday, working alongside global co-ordinators CICC ... Already a subscriber? Login Continue reading this article Try full access to GlobalCapital Free trial Want to learn more? View subscription options HOME ASIA EQUITY IPOS
